| 产品描述: | JNJ-63576253 (TRC-253)是一种有效且具有选择性的下一代 androgen receptor (AR) 拮抗剂,IC50 为 6.9 nM。JNJ-63576253 在 WT 和 LBD 突变、enzalutamide耐药的前列腺癌模型中显示出强大的抑制作用 |
| 靶点: |
Androgen receptor(Cell-free assay):6.9 nM;ndrogenReceptor |
| 体外研究: |
JNJ-63576253 can inhibit transcriptional activity in reporter assays, cellular proliferation, and AR downstream target gene expression, as a potent and selective next-generation AR pathway inhibitor. |
| 体内研究: |
JNJ-63576253 causes tumor growth inhibition in an enzalutamide-resistant LNCaP F877 L xenograft model. |
| 细胞实验: |
Cell lines: HepG2, VCaP, PC3, LNCaP AR/cs, LNCaP F877L Concentrations: 0.0001 μΜ-1.5 μM Incubation Time: 6 h, 24h Method: LNCaP AR/cs, LNCaP F877L, VCaP, and PC3 are seeded at densities of 5,000 or 250 cells per well into 96-well plates and incubated overnight. Following compound treatment, the cells are incubated for 6 days for assessing proliferation. For transcriptional reporter assays, LNCaP reporter lines are seeded at a density of 10,000 cells per well, incubated overnight, then treated for 24 hours with JNJ-63576253 in the presence of 0.1 nmol/L R1881. After treatment, cells are assayed using the SteadyGlo-luciferase Kit. |
| 动物实验: |
Animal Models: Castrated male rats (Sprague Dawley;ages 42–45 days) Dosages: 10, 30, 50 mg/kg Administration: p.o. |
| 参考文献: |
1. Jonathan R Branch, et al. Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer. Mol Cancer Ther. 2021 May;20(5):763-774. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.855 ml |
9.277 ml |
18.554 ml |
| 5 mM |
0.371 ml |
1.855 ml |
3.711 ml |
| 10 mM |
0.186 ml |
0.928 ml |
1.855 ml |
| 50 mM |
0.037 ml |
0.186 ml |
0.371 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |